SHANGHAI, Dec 3 (Reuters) - China stocks ended lower on
Thursday, weighed down by fresh tensions between Beijing and
Washington after the U.S. House of Representatives passed a bill
that threatens to delist Chinese companies from U.S. stock
** Both Democrats and Donald Trump's fellow Republicans echoed
the president's hard line against Beijing, which has became
fiercer this year as Trump blamed China for the coronavirus
ravaging the United States.
** Sino-U.S. relations have been a key factor influencing market
sentiment since the outbreak of the trade war in 2018. On
Wednesday, U.S. President-elect Joe Biden told the New York
Times that he will not immediately cancel the trade agreement
that President Donald Trump struck with China nor take steps to
remove tariffs on Chinese exports.
** At the close, the Shanghai Composite index was down
0.21% at 3,442.14, while the blue-chip CSI300 index
was down 0.2%.
** The smaller Shenzhen index ended up 0.08% and the
start-up board ChiNext Composite index was higher by
** Vaccine-related stocks helped limit losses in the index,
after the Institute of Microbiology at the Chinese Academy of
Sciences said it worked with China's Chongqing Zhifei
to carry out phase III trial of a coronavirus
vaccine in China's Hunan province in November. The company was
up 4.6% at market close, while the healthcare sub-index
** Vaccine stocks were also boosted after Britain approved
Pfizer Inc's COVID-19 vaccine, raising hopes that the
coronavirus pandemic, which has so far killed nearly 1.5 million
people globally, could potentially be brought under control.
** Around the region, MSCI's Asia ex-Japan stock index
was firmer by 0.27%, while Japan's Nikkei index
closed up 0.03%.
(Reporting by Winni Zhou and Andrew Galbraith; Editing by Vinay